Better Buy: GlaxoSmithKline vs. Pfizer

Better Buy: GlaxoSmithKline vs. Pfizer

GlaxoSmithKline's (NYSE: GSK) adjuvant is being used in three clinical-stage COVID-19 vaccine candidates, but its shares have plunged 20% year to date. Pfizer (NYSE: PFE) is arguably the clear leader in the race, but its shares are down around 7%. The reason behind these declines is that both GlaxoSmithKline and Pfizer have a lot more going on than just their COVID-19 programs.